TY  - JOUR
AU  - Sopić, Miron
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5555
AB  - The relentless struggle with the aftermath of COVID-19 has driven the medical community to seek innovative methods for predicting and managing the disease’s complications. Complications such as an overactive immune response, manifesting as cytokine storms, and shifts toward a procoagulant state not only exacerbate symptoms but also elevate the risk of mortality and long-term health issues. Consequently, there is a pressing need for novel diagnostic tools and therapeutic strategies that not only track disease progression and complications but also serve as potential drug targets or can be influenced by pharmacological interventions. In the presented study by Perez-Pons et al.1 titled “MicroRNA-centered theranostics for pulmoprotection in critical COVID-19,” the authors shed light on the promising role of microRNAs (miRNAs) as dual-purpose theranostic agents. By focusing on a multicenter cohort of intensive care unit (ICU) survivors, the research elucidates the potential of miRNAs in mitigating diffusion impairment—a common but debilitating consequence of severe infection. This commentary aims to contextualize these findings within the broader spectrum of molecular and cellular therapies, underlining their significance and implications they pose for the field.

Since the outbreak of the COVID-19 pandemic, a significant number of survivors, particularly those who experienced severe illness, have continued to face post-acute pulmonary sequelae. COVID-19 survivors often experience a spectrum of long-term lung issues, with dyspnea being a common symptom reported by 42%–66% of individuals within 60–100 days post-infection.2 Individuals who experienced severe forms of COVID-19, particularly those in need of intensive respiratory support, are more likely to suffer from long-lasting lung issues.2 This includes diffusion impairment, which refers to a decreased ability of the lungs to transfer oxygen from the air into the bloodstream, as well as observable lung damage like pulmonary fibrosis on medical imaging.2 The persistence of these health issues among survivors indicates a substantial impact on their quality of life and the healthcare system, stressing the urgency in identifying effective interventions and support mechanisms for those affected.
T2  - Molecular Therapy: Nucleic Acids
T1  - Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics
VL  - 35
IS  - 1
SP  - 102152
DO  - 10.1016/j.omtn.2024.102152
ER  - 

@article{
author = "Sopić, Miron",
year = "2024",
abstract = "The relentless struggle with the aftermath of COVID-19 has driven the medical community to seek innovative methods for predicting and managing the disease’s complications. Complications such as an overactive immune response, manifesting as cytokine storms, and shifts toward a procoagulant state not only exacerbate symptoms but also elevate the risk of mortality and long-term health issues. Consequently, there is a pressing need for novel diagnostic tools and therapeutic strategies that not only track disease progression and complications but also serve as potential drug targets or can be influenced by pharmacological interventions. In the presented study by Perez-Pons et al.1 titled “MicroRNA-centered theranostics for pulmoprotection in critical COVID-19,” the authors shed light on the promising role of microRNAs (miRNAs) as dual-purpose theranostic agents. By focusing on a multicenter cohort of intensive care unit (ICU) survivors, the research elucidates the potential of miRNAs in mitigating diffusion impairment—a common but debilitating consequence of severe infection. This commentary aims to contextualize these findings within the broader spectrum of molecular and cellular therapies, underlining their significance and implications they pose for the field.

Since the outbreak of the COVID-19 pandemic, a significant number of survivors, particularly those who experienced severe illness, have continued to face post-acute pulmonary sequelae. COVID-19 survivors often experience a spectrum of long-term lung issues, with dyspnea being a common symptom reported by 42%–66% of individuals within 60–100 days post-infection.2 Individuals who experienced severe forms of COVID-19, particularly those in need of intensive respiratory support, are more likely to suffer from long-lasting lung issues.2 This includes diffusion impairment, which refers to a decreased ability of the lungs to transfer oxygen from the air into the bloodstream, as well as observable lung damage like pulmonary fibrosis on medical imaging.2 The persistence of these health issues among survivors indicates a substantial impact on their quality of life and the healthcare system, stressing the urgency in identifying effective interventions and support mechanisms for those affected.",
journal = "Molecular Therapy: Nucleic Acids",
title = "Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics",
volume = "35",
number = "1",
pages = "102152",
doi = "10.1016/j.omtn.2024.102152"
}

Sopić, M.. (2024). Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics. in Molecular Therapy: Nucleic Acids, 35(1), 102152.
https://doi.org/10.1016/j.omtn.2024.102152

Sopić M. Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics. in Molecular Therapy: Nucleic Acids. 2024;35(1):102152.
doi:10.1016/j.omtn.2024.102152 .

Sopić, Miron, "Exploring pulmoprotection in COVID-19: Moving toward microRNA-based theranostics" in Molecular Therapy: Nucleic Acids, 35, no. 1 (2024):102152,
https://doi.org/10.1016/j.omtn.2024.102152 . .